Kinnate Biopharma Inc. (KNTE) has a consensus analyst rating of Hold, based on 6 analysts covering the stock. Of those, 2 recommend buying, 4 recommend holding, and 0 recommend selling.
The analyst consensus price target for KNTE is $30.00, representing a +1,032.1% upside from the current price of $2.65. Price targets range from a low of $30.00 to a high of $30.00.
